Internationally recognized fibrosis expert with over 200 publications and multiple patents. Dr. Feghali-Bostwick is a distinguished professor at the Medical University of South Carolina (MUSC), where she has dedicated her career to understanding and treating fibrotic diseases. Her groundbreaking research has been published in leading scientific journals and has significantly advanced the field's understanding of pulmonary fibrosis mechanisms. Dr. Feghali-Bostwick has received numerous awards for her innovative research, including the Zucker Institute Admiral Albert J. Baciocco Innovator of the Year Award, the Pitt Innovator Award, and the American Thoracic Society Recognition Award for Scientific Accomplishments. She was also inducted as Fellow in the National Academy of Inventors. As a Co-Founder and Acting Chief Scientific Officer, she brings unparalleled scientific expertise and credibility to the company. Her extensive patent portfolio demonstrates her ability to translate basic research into innovative therapeutic approaches.
Proven track record raising $250M+ and advancing therapeutics through Phase III trials. Steve brings extensive experience in building and leading biopharmaceutical companies from early stages through clinical development. At Peregrine Pharmaceuticals and AVID Bioservices, he successfully raised over $250 million in capital and navigated complex regulatory pathways to advance lead products into late-stage clinical trials. His strategic vision combines scientific rigor with business acumen, enabling him to build strong partnerships with investors, regulatory agencies, and commercial partners. Steve's leadership style emphasizes data-driven decision making while maintaining focus on the ultimate goal: delivering life-changing therapies to patients with serious unmet medical needs.
Raised $500M+ in capital and achieved successful exit through acquisition. Paul is an accomplished financial executive with 30+ years of finance experience and a proven track record in the biotechnology sector. At various public and private companies, he was instrumental in raising over $500 million in capital in the biotechnology and medical technology sectors through various financing mechanisms, including venture capital, private and public equity instruments, strategic partnerships and M&A exits. His deep understanding of biotech financing, combined with his operational experience, makes him a valuable partner in navigating the complex landscape of drug development and related funding.
25+ years leading quality and regulatory operations for worldwide commercial products. Connie Chang is a biopharmaceutical quality and regulatory executive with leadership experience spanning development through commercialization of biological, gene, cell, and enzyme-based therapeutics, as well as critical materials and mRNA. She has held senior leadership roles at Peregrine Pharmaceuticals, Avid Bioservices, NantKwest, BioMarin Pharmaceuticals Inc., TriLink Biotechnologies, and RadioMedix Inc. At BioMarin, she led Global Quality GMP Operations for products marketed in over 70 countries, and at TriLink served as Vice President of Quality and Regulatory, supporting RNA and critical reagent manufacturing. At RadioMedix, she leads quality strategy and execution to support organization's advancement toward commercial readiness. Throughout her career, Connie has successfully led and hosted regulatory inspections supporting market launch and market expansion, including pre-approval inspections (PAIs) and global health authority inspections.
30+ years building and managing IP portfolios in biotechnology. Dr. Fussey brings over three decades of expertise in intellectual property strategy, patent prosecution, and portfolio management. Having both law firm and corporate experience, including at Peregrine Pharmaceuticals and Mosaic ImmunoEngineering, she built comprehensive IP portfolios that protected innovative technologies while maximizing commercial value and strategic flexibility. Her deep scientific background, combined with extensive legal and business experience, enables her to craft IP strategies that align with corporate objectives. Shelley has successfully navigated complex patent landscapes, defended against challenges, and negotiated licensing agreements with universities, start-ups and major pharmaceutical companies. Her work ensures freedom-to-operate while building robust protection around the company's innovations.